scroll down

About us - Zenitar

  • Zenitar was established in April 2019.

  • A start-to-end innovative drug development company.  

  • Focusing on oncology, autoimmunity and inflammatory diseases.

  • Three innovative drugs covering six indications on clinical trial phase I and phase II.                    

  • 2019+

    Established Date

  • 70+

    Scientists

  • 30+

    Patents

Learn more >> Learn more >>

  • 01

    Structural Biology Platform

    Structural Biology Platform

    Zenitar's structural biology platform efficiently utilizes X-ray crystallography and cryo-EM to analyze protein-drug complex structures for pipeline targets.

    Learn more >> Learn more >>

  • 02

    AI-Driven Drug Design Platform

    AI-Driven Drug Design Platform

    Zenitar's AI-driven platform, AlloMol.AI, supports target identification, binding site prediction, molecular design, and druggability assessment, greatly boosting the efficiency of our internal pipeline development.

    Learn more >> Learn more >>

  • 03

    Organoids Screening Platform

    Organoids Screening Platform

    Zenitar's Organoid Screening Platform, adopting a "from clinic to clinic" approach, has established a proprietary organoid culture system for solid tumors.

    Learn more >> Learn more >>

  • 04

    Patient-Derived Tumor Model Screening Platform

    Patient-Derived Tumor Model Screening Platform

    Zenitar's Patient-Derived Organoid Xenograft (PDOX) Screening Platform offers a powerful and clinically relevant tool for cancer research and drug development.

    Learn more >> Learn more >>

Product Pipeline